trending Market Intelligence /marketintelligence/en/news-insights/trending/t2tc4D3RovRvLh8XUWb0Sw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Pfizer completes exchange, tender offers for notes

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Pfizer completes exchange, tender offers for notes

Pfizer Inc. completed the private offer to exchange its outstanding £1.5 billion 6.500% notes due 2038 with newly issued debt securities.

The company also completed its offer to purchase for cash any and all of its outstanding 2038 notes.

The company said £833.5 million of outstanding 2038 notes were validly tendered and accepted and subsequently canceled in the exchange offer, while £196.6 million of outstanding 2038 notes were validly tendered and accepted and subsequently canceled in the tender offer.

Following the completion, £470 million of the 2038 notes remains outstanding.

In connection with the exchange offer, the company issued £1.38 billion of 2.735% notes due 2043 in exchange for the validly tendered and accepted 2038 notes.

The new notes are unsecured general obligations of Pfizer and rank equally with all other unsecured and unsubordinated indebtedness of the company.

The 2038 notes offers expired on Dec. 14.